COMparison Between All immunoTherapies for Multiple Sclerosis.
- Sponsor
- Karolinska Institutet
- Study ID
- NCT03193866
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUGComparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis
Study Details
The overarching goal of this study is to determine whether rituximab (RTX) offers effectiveness and safety advantages over other commonly used approved Disease-Modifying Drugs (DMT) in the largest real-world population-based structured prospective follow-up cohort of Relapsing-Remitting Multiple Sclerosis (RRMS) patients. The study will include both treatment naïve patients starting their first DMT and patients switching from a previous first line DMT (escalation/second-line).
Key Dates
- Start date
- Jun 2, 2017
- Status verified
- Mar 2025
- Primary completion
- Mar 31, 2022
- Completion
- Mar 31, 2022
Study Design
- Enrollment
- 3,526 participants (actual)
Primary Outcome Measure
Confirmed Disease Progression in Patients With Expanded Disability Status Scale (EDSS) <2.5 at Baseline [ Time Frame: 3 years ]